HemaCare Corp. Reports Loss in Second Quarter

HemaCare Corp., a Sherman Oaks company that provides blood-related services, reported that it lost $295,576 in the second quarter that ended June 30, compared to a profit of $27,804 a year earlier. The company’s revenues increased 31% in the second quarter to $1.87 million from $1.42 million a year before.

HemaCare attributed the loss in part to the costs of beginning clinical trials of a proposed AIDS treatment, called passive hyper-immune therapy. The therapy involves treating AIDS patients with infusions of sterilized blood plasma from donors who are healthy but are infected with the virus that causes AIDS. The company also said that its 4-month-old HemaCare Clinical Laboratories division lost money.

For the first six months of 1990, HemaCare lost $232,934, compared to a profit of $206,802 last year. HemaCare’s six month revenues jumped 33% to $3.61 million from $2.71 million a year earlier.